Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immunzellkalender 2025
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy
MS Treatments
Jahr
Publikationsjahr
2002
Autoren
Autorenliste der Publikation
Ziemssen T, Kümpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R.
Verlag
Publisher-Information
Brain 2002;125(11):2381-2391.
Link
Zur Publikation (externer Server)
https://doi.org/10.1093/brain/awf252
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
MSZ
Treatments
2002
Editorial: Digital twins in medicine—transition from theoretical concept to tool used in everyday care
MASC
Jahr
2025
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
MS Treatments
Jahr
2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS
MS Treatments
Jahr
2025
Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint
MASC
Jahr
2025
A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?
MS Treatments
Jahr
2025